Treatment Strategies for Central Nervous System Effects in Primary and Secondary Haemophagocytic Lymphohistiocytosis in Children
Open Access
- 1 February 2022
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 24 (2) , 55-76
Abstract
Purpose of Review: This review presents an appraisal of current therapeutic options for the treatment of central nervous system haemophagocytic lymphohistiocytosis (CNS-HLH) in the context of systemic disease, as well as when CNS features occur in isolation. We present the reader with a diagnostic approach to CNS-HLH and commonly used treatment protocols. We discuss and evaluate newer treatments on the horizon. Recent Findings: Mortality is high in patients who do not undergo HSCT, and while larger studies are required to establish benefit in many treatments, a number of new treatments are currently being evaluated. Alemtuzumab is being used as a first-line treatment for CNS-HLH in a phase I/II multicentre prospective clinical trial as an alternative to traditional HLH-1994 and 2004 protocols. It has also been used successfully as a second-line agent for the treatment of isolated CNS-HLH that is refractory to standard treatment. Ruxolitinib and emapalumab are new immunotherapies that block the Janus kinase—Signal Transducer and Activator of Transcription (JAK-STAT) pathway that have shown efficacy in refractory HLH, including for CNS-HLH disease. Summary: Treatment of CNS-HLH often requires HLH-94 or 2004 protocols followed by haematopoietic stem cell transplantation (HSCT) to maintain remission, although relapse can occur, particularly with reduced intensity conditioning if donor chimerism falls. CNS features have been shown to improve or stabilise following HSCT in CNS-HLH in the context of systemic disease and in isolated CNS-HLH. Encouraging reports of early cohort studies suggest alemtuzumab and the Janus kinase (JAK) inhibitor ruxolitinib offer potential salvage therapy for relapsed and refractory CNS-HLH. Newer immunotherapies such as tocilizumab and natalizumab have been shown to be beneficial in sporadic cases. CNS-HLH due to primary gene defects may be amenable to gene therapy in the future.Keywords
This publication has 83 references indexed in Scilit:
- Central nervous system (CNS) involvement is a critical prognostic factor for hemophagocytic lymphohistiocytosisThe Korean Journal of Hematology, 2012
- Neuroradiologic findings and follow‐up with magnetic resonance imaging of the genetic forms of haemophagocytic lymphohistiocytosis with CNS involvementPediatric Blood & Cancer, 2011
- Reduced‐intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forwardBritish Journal of Haematology, 2011
- Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and managementClinical and Experimental Immunology, 2011
- Hemophagocytic lymphohistiocytosis with neurological presentation: MRI findings and a nearly miss diagnosisNeurological Sciences, 2011
- Frequency and development of CNS involvement in Chinese children with hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2009
- The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosisBone Marrow Transplantation, 2008
- Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosisBritish Journal of Haematology, 2007
- Biology and treatment of familial hemophagocytic lymphohistiocytosis: Importance of perforin in lymphocyte‐mediated cytotoxicity and triggering of apoptosisMedical and Pediatric Oncology, 2002
- Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosisThe Journal of Pediatrics, 1997